Zevra Therapeutics (ZVRA) Cash & Equivalents (2014 - 2026)

Zevra Therapeutics' Cash & Equivalents history runs 13 years deep, the most recent figure standing at $95.6 million for Q1 2026.

• Quarterly Cash & Equivalents rose 156.01% year-over-year to $95.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $95.6 million (up 156.01% YoY) and the FY2025 annual result came in at $62.4 million, up 84.72% from the prior year.
• Cash & Equivalents was $95.6 million for Q1 2026 at Zevra Therapeutics, up from $62.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $95.6 million in Q1 2026 and bottomed at $33.8 million in Q4 2024.
• A 5-year average of $53.7 million and a median of $47.7 million in 2025 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents tumbled 46.72% — and 2026, when it jumped 156.01%.
• Zevra Therapeutics' Cash & Equivalents stood at $65.5 million in 2022, then tumbled by 34.24% to $43.0 million in 2023, then slipped by 21.52% to $33.8 million in 2024, then surged by 84.72% to $62.4 million in 2025, then jumped by 53.18% to $95.6 million in 2026.
• Business Quant data shows ZVRA's Cash & Equivalents at $95.6 million in Q1 2026, $62.4 million in Q4 2025, and $54.4 million in Q3 2025.